On The Pen GLP-1 News

Dave Knapp GLP-1 Industry Insider
  • 5.0 (1)
  • MEDICINE

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

  1. NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

    2D AGO

    NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

    Send a text This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war. 00:00 – Cold Open: Lilly vs Novo Shock Timing Dave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match. 03:20 – Novo Nordisk Price Cuts Explained Deep dive into Novo’s plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning. 07:25 – Tirzepatide vs Semaglutide Head to Head Trial Breakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially. 11:55 – Market Reaction and Strategic Implications Discussion of stock movement, competitive signaling, and how Novo’s pricing move may blunt Lilly’s trial victory. 14:25 – Novo Triple Agonist Data Drops Shift into Novo’s early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists. 16:00 – Comparing Novo’s Triple to Retatrutide Analysis of weight loss percentages versus Lilly’s retatrutide data and the caution required when comparing across trials. 18:15 – The Triple Agonist Era Broader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term. 20:00 – Clinical Trial Results vs Real World Reality Reminder that clinical trial outcomes do not automatically translate to everyday patient experience. 22:30 – Data Refresher on Allurion Ballon Approval Quick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    27 min
  2. Wegovy vs Zepbound in 2026: New Higher Dose

    FEB 17

    Wegovy vs Zepbound in 2026: New Higher Dose

    Send a text Wegovy’s new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn’t which drug helps you lose more weight—it’s which one treats your underlying metabolic disease more effectively. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    21 min
  3. Compound Tirzepatide: Time to Stock Up?

    FEB 10

    Compound Tirzepatide: Time to Stock Up?

    Send a text This week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly’s earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    32 min
  4. Eli Lilly Earnings Call Q4 2025 Recap

    FEB 4

    Eli Lilly Earnings Call Q4 2025 Recap

    Send a text This week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    22 min
  5. Once Monthly GLP-1 Injection? Pfizer Drops New Data

    FEB 3

    Once Monthly GLP-1 Injection? Pfizer Drops New Data

    Send a text This week on On The Pen: The Weekly Dose, we break down Pfizer’s $10 billion bet on obesity medicine and whether it’s shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer’s once-monthly GLP-1 candidate (formerly Metsera’s asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies. We also talk strategy, maintenance dosing, combination GLP-1 + amylin approaches, pricing pressures, cash-pay access, and what this all means for patients navigating a rapidly changing obesity treatment landscape. Plus, earnings week insights, where Pfizer may be headed next, and why pricing and access, not just weight-loss percentages, may end up being the real disruptors. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    22 min
  6. PCOS and Tirzepatide Clinical Trial. Finally

    JAN 27

    PCOS and Tirzepatide Clinical Trial. Finally

    Send a text Can Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    19 min
  7. Over The Counter GLP-1 Prediction

    JAN 20

    Over The Counter GLP-1 Prediction

    Send a text In this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn’t radical speculation, it’s a pattern already in motion. Drawing on FDA signals, past regulatory precedent with Orlistat, recent pricing negotiations, softened safety language, and public comments from pharmaceutical executives, Dave lays out the case that low-dose oral GLP-1s could be the first step toward OTC access. This episode connects the dots between regulation, access, pricing, and normalization of obesity treatment, and explains why the people laughing today may be asking how they missed it tomorrow. 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    21 min
  8. GLP-1 PLUS Gastric Balloon for added Weight Loss!

    JAN 19

    GLP-1 PLUS Gastric Balloon for added Weight Loss!

    Send a text Shantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when patients can realistically expect access. We talk real world weight loss results, safety, availability in the US, and how Allurion fits into the broader obesity treatment conversation alongside GLP-1 medications and bariatric options. This is a clear, no hype discussion for patients who want more tools and better choices in obesity care. More Info: OTPLinks.com 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A MEMBER: https://www.youtube.com/channel/UCDocQ-4IhVS3ihy_dW7nSKw/join 👉 My Amazon Affiliate Store: https://www.amazon.com/shop/manonthemounjaroonthepen WATCH MORE! 📺 We're Live M/W/F at 11 central: onthepen.tv 📲 Contact Me: dave@onthepen.com Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit onthepen.com.

    32 min
See All (175)

About

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

Information

  • Creator
    Dave Knapp GLP-1 Industry Insider
  • Years Active
    2K
  • Episodes
    175
  • Rating
    Clean
  • Copyright
    © 2026 On The Pen GLP-1 News
  • Show Website
    On The Pen GLP-1 News

You Might Also Like